IMMUCELL CORP /DE/
ICCC · XNASCIK 811641fmd_0R77KSN7XC4PM5DFQBR1H806A6Manufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 10 | 11 | 14 | 15 | 19 | 19 | 17 | 26 | 28 |
| Cost of revenue | 4 | 5 | 6 | 7 | 8 | 11 | 11 | 14 | 19 | 16 |
| Gross profit | 5 | 5 | 5 | 7 | 7 | 9 | 8 | 4 | 8 | 11 |
| Research and development | 1 | 2 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
| Selling, general and administrative | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 |
| Total operating expenses | 5 | 5 | 7 | 8 | 8 | 8 | 10 | 10 | 10 | 10 |
| Operating income | 1 | (0) | (1) | (1) | (1) | 0 | (2) | (6) | (2) | 2 |
| Interest expense | – | – | – | – | – | 0 | 0 | 0 | 1 | 0 |
| Interest and investment income | – | – | – | – | – | – | – | – | 0 | 0 |
| Other non-operating income (expense) | – | – | – | (0) | 0 | (0) | (0) | (0) | (1) | (3) |
| Income before taxes | 1 | (0) | (2) | (1) | (1) | (0) | (2) | (6) | (2) | (1) |
| Income tax expense | 0 | (0) | 0 | 0 | (0) | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 1 | (0) | (2) | (1) | (1) | (0) | (2) | (6) | (2) | (1) |
| Net income | 1 | (0) | (2) | (1) | (1) | (0) | (2) | (6) | (2) | (1) |